{
  "drugs": [
    {
      "drug": "sotorasib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalent binding to GDP-bound KRAS G12C",
      "fda_status": "Approved (NSCLC, CRC combo)"
    },
    {
      "drug": "adagrasib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Covalent binding to GDP-bound KRAS G12C",
      "fda_status": "Approved (NSCLC, CRC)"
    },
    {
      "drug": "daraxonrasib (RMC-6236)",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "RAS(ON) multi-selective; binds active GTP-RAS",
      "fda_status": "Breakthrough Therapy (PDAC)"
    },
    {
      "drug": "MRTX1133",
      "proteins": [
        "KRAS G12D"
      ],
      "mechanism": "Direct switch-II pocket binding to KRAS G12D",
      "fda_status": "Phase 1/2 (PDAC)"
    },
    {
      "drug": "VS-7375 (GFH375)",
      "proteins": [
        "KRAS G12D"
      ],
      "mechanism": "Oral direct KRAS G12D inhibition",
      "fda_status": "Fast Track (PDAC)"
    },
    {
      "drug": "zoldonrasib",
      "proteins": [
        "KRAS G12D"
      ],
      "mechanism": "Direct KRAS G12D inhibition",
      "fda_status": "Entering clinic"
    }
  ],
  "cancer_type": "pancreatic cancer",
  "protein_targets": [
    "KRAS",
    "KRAS G12D",
    "CD44"
  ]
}